Washington, D.C.—June 8, 2015— The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the announcement of tentative approval by the U.S. Food and Drug Administration of a new antiretroviral treatment (ART) formulation that will make it easier for children living with HIV to ingest their medication. The oral pellets, manufactured by Indian generic medicines manufacturer CIPLA, contain an antiretroviral formulation of lopinavir and ritonavir (LPV/r) that can be mixed into a child’s food.